Revenue
Cost
Profit
| Item | Category | Value | YoY |
|---|---|---|---|
| Net revenues | revenue | 15.00B | 12.43% |
| Operating earnings | profit | 3.99B | 6.88% |
| Total operating costs and expenses | cost | 11.01B | 14.59% |
| Earnings before income tax expense | profit | 1.04B | -37.45% |
| Other nonoperating income (expense) | revenue | 2.31B | 59.58% |
| Interest income (expense), nonoperating | revenue | 645.00M | 2.87% |
| Cost of products sold | cost | 4.22B | 5.40% |
| Selling, general and administrative | cost | 3.58B | 8.65% |
| Research and development | cost | 2.47B | 19.59% |
| Acquired ipr&d and milestones | cost | 744.00M | 200.00% |
| Net earnings | profit | 697.00M | -45.93% |
| Income tax expense | cost | 342.00M | -8.06% |
| Net earnings attributable to abbvie inc. | profit | 695.00M | -45.96% |
| Net earnings attributable to noncontrolling interest | cost | 2.00M | -33.33% |
| Segment | Value | YoY |
|---|---|---|
| SKYRIZI | 4.48B | 30.89% |
| RINVOQ | 2.12B | 23.34% |
| Other Products | 1.02B | -18.20% |
| Botox Therapeutic | 1.01B | 16.51% |
| Vraylar | 905.00M | 18.30% |
| VENCLEXTA | 770.00M | 15.79% |
| H U M I R A | 688.00M | -38.63% |
| Botox Cosmetic | 668.00M | 20.14% |
| Imbruvica | 556.00M | -24.66% |
| MAVYRET | 351.00M | 14.71% |
| Ubrelvy | 339.00M | 41.25% |
| Qulipta | 296.00M | 53.37% |
| Other Aesthetics | 286.00M | -9.21% |
| Linzess/Constella | 283.00M | 91.22% |
| Juvederm Collection | 232.00M | 0.43% |
| Vyalev | 201.00M | 219.05% |
| Elahere | 198.00M | 10.61% |
| Other Neuroscience | 125.00M | -19.35% |
| Epkinly | 83.00M | 62.75% |
| Others | 385.00M | 8.45% |
| Item | Category | Value | YoY |
|---|---|---|---|
| Accounts receivable, net | assets | 12.48B | |
| Cash and equivalents | assets | 9.39B | |
| Prepaid expenses and other | assets | 6.61B | |
| Inventories | assets | 5.05B | |
| Total current assets | assets | 33.53B | |
| Intangible assets, net | assets | 50.87B | |
| Goodwill | assets | 35.57B | |
| Other assets | assets | 10.54B | |
| Property and equipment, net | assets | 5.69B | |
| Investments | assets | 268.00M | |
| Total assets | assets | 136.46B | |
| Long-term debt | liabilities | 64.53B | |
| Total current liabilities | liabilities | 42.10B | |
| Other long-term liabilities | liabilities | 34.11B | |
| Deferred income taxes | liabilities | 2.33B | |
| Accounts payable and accrued liabilities | liabilities | 33.77B | |
| Current portion of long-term debt | liabilities | 8.33B |
| Item | Value |
|---|---|
| Change in fair value of contingent consideration liabilities | 2.39B |
| Amortization of intangible assets | 1.75B |
| Acquired ipr&d and milestones | 744.00M |
| Net earnings | 697.00M |
| Stock-based compensation | 444.00M |
| Depreciation | 188.00M |
| Non-cash litigation reserve adjustments, net of cash payments | 150.00M |
| Deferred income taxes | 137.00M |
| Increase (decrease) in accounts receivable | 87.00M |
| Other noncash income (expense) | -22.00M |
| Income tax assets and liabilities, net | -81.00M |
| Increase (decrease) in prepaid expense and other assets | -150.00M |
| Increase (decrease) in inventories | -184.00M |
| Payment for contingent consideration liability, operating activities | -722.00M |
| Accounts payable and other liabilities | -1.59B |
| Item | Value |
|---|---|
| Payment for (proceeds from) other investing activity | -43.00M |
| Payments to acquire property, plant, and equipment | -265.00M |
| Cash outflows related to acquisitions and investments | -266.00M |
| Item | Value |
|---|---|
| Proceeds from issuance of long-term debt | 7.99B |
| Other, net | 2.00M |
| Net change in commercial paper borrowings with original maturities of three months or less | -499.00M |
| Payments for repurchase of common stock | -1.49B |
| Repayments of other short-term borrowings | -2.00B |
| Payments of dividends | -3.09B |
| Item | Value |
|---|---|
| Cash and cash equivalents, beginning of period | 5.23B |
| Cash and cash equivalents, end of period | 9.39B |
Instantly decode complex 10-K and 10-Q data. Explore interactive Sankey diagrams for income and balance sheets, and intuitive waterfall charts for cash flows.
Search for a company and select a report on the left panel.
Request Stock Support